PA-080 **CRYPTOCOCCAL MENINGOENCEPHALITIS IN HIV-INFECTED PATIENTS IN MADAGASCAR: HIGH PREVALENCE AND LETHALITY AND THERAPEUTIC CHALLENGES**

Rivo Rakotoarivelo,¹ Mihaja Raberahona,² Njary Randriamampionona,³ Rabezanahary Andriamihaja,⁴ Tahinamandranto Rasamoelina,³ Muriel Cornet,⁵ Mamy Jean De Dieu Randria,² Thomas Benet,⁶ Philippe Vanhems,⁶ Mala Rakoto Andrianarivelo³. ¹CHU Tamboho Fianarantsoa, Madagascar; ²HUJR de Befelatanana, Madagascar; ³CICM, Madagascar; ⁴CHU Analakinina, Madagascar; ⁵CHU de Grenoble, France; ⁶HEH, France

10.1136/bmjgh-2016-000260.112

Background In Madagascar the epidemiology of cryptococcosis is poorly documented. The main objective of this study was to estimate the prevalence of Cryptococcal meningoencephalitis (CM) in Madagascar and to describe the presentation of the cases.

Methods This is an observational transverse study conducted in the hospitals of Antananarivo and Toamasina cities. Between 3 November 2014 and 8 June 2016, HIV-infected adults presenting CD4 cell count $\leq 200/\text{mm}^3$ were selected. The cryptococcal antigen (CrAg) was screened in the blood using a lateral flow immunoassay (IMMYCrAg® LFA). If the result was positive and the patient symptomatic, CrAg was checked in the cerebrospinal fluid (CSF) and examined with India ink, and culture was performed. The isolated strains were subsequently analysed using MALDI-TOF and an antifungal susceptibility test was performed using the E-test method (BioMérieux).

Results Overall, 118 patients were included. The mean CD4 cell count was $86.4/\text{mm}^3$ ($\text{SD} \pm 60.6$) and 35.6% of the patients were under ARV therapy at baseline. HIV-1 viral load of 88.5% of patients was positive. We compared the clinical characteristics of patients with cryptococcal infections to those of controls without CM. Eleven cases of CM were identified corresponding to a prevalence of 15.1% (95% CI: 7.8–25.4%). *Cryptococcus neoformans* var. *grubii* (serotype A) was isolated. Fever, headache, neck pain

and night sweats were the most common signs. In 7 cases, CrAg titres in the CSF were very high (≥ 2560) and did not decrease even 2 months post-treatment. The Case Fatality Rate was unacceptably high (69%).

Conclusions Overall, prevalence of cryptococcal meningo-encephalitis (CM) in Madagascar was very high (15.1%) compared to that observed in some Sub-Saharan African countries. The point-of-care LFA CrAg test was confirmed to be reliable and cost-effective for the diagnosis. Challenges to facilitate access to more effective molecules to treat patients with CM include heavy administrative formalities linked to drug importation and low level of priority in implementing the national control programme.